Analysis of PD-L1 and CD3 Expression in Glioblastoma Patients and Correlation with Outcome: A Single Center Report
Authors:
- Navid SobhaniNavid Sobhani
- Victoria BouchèVBVictoria Bouchè
- Giovanni AldegheriGAGiovanni Aldegheri
- Andrea RoccaAndrea Rocca
- Alberto D’angeloADAlberto D’angelo
- Fabiola GiudiciFGFabiola Giudici
- Cristina BottinCBCristina Bottin
- Carmine Antonio DonofrioCarmine Antonio Donofrio
- Maurizio PinamontiMPMaurizio Pinamonti
- Benvenuto FerrariBFBenvenuto Ferrari
- Stefano PanniSPStefano Panni
- Marika CominettiMCMarika Cominetti
Open Access
- 22 January 2023
- journal article
- research article
- Published by MDPI AG in Biomedicines
- Vol. 11 (2) , 311
Abstract
With the advent of immunotherapies, the field of cancer therapy has been revived with new hope, especially for cancers with dismal prognoses, such as the glioblastoma multiforme (GBM). Currently, immunotherapies should potentiate the host’s own antitumor immune response against cancer cells, but it has been documented that they are effective only in small subsets of patients. Therefore, accurate predictors of response are urgently needed to identify who will benefit from immune-modulatory therapies. Brain tumors are challenging in terms of treatments. The immune response in the brain is highly regulated, and the immune microenvironment in brain metastases is active with a high density of tumor-infiltrating lymphocytes (TILs, CD3+ T cells) in certain patients and, therefore, may serve as a potential treatment target. In our study, we performed immunohistochemistry for CD3 and PD-L1 along the routine assessment of the O6-methylguanine-methyltransferase (MGMT) promoter methylation status and the IDH1 and 2 status in a single center cohort of 69 patients with GBM (58 primary tumors and 11 recurrences) who underwent standard multimodal therapies (surgery/radiotherapy/adjuvant temozolamide). We analyzed the association of PD-L1 tumor expression and TILs with overall survival (OS). The PD-L1 expression was observed in 25 of 58 (43%) newly diagnosed primary glioblastoma specimens. The sparse-to-moderate density of TILs, identified with CD3+ expression, was found in 48 of 58 (83%) specimens. Neither PD-L1 expression nor TILs were associated with overall survival. In conclusion, TILs and/or PD-L1 expression are detectable in the majority of glioblastoma samples, and even if they slightly relate to the outcome, they do not show a statistically significant correlation.Keywords
Funding Information
- MEDnoTE srl
This publication has 54 references indexed in Scilit:
- PD‐1 as a potential target in cancer therapyCancer Medicine, 2013
- Anti-PD-1 Blockade and Stereotactic Radiation Produce Long-Term Survival in Mice With Intracranial GliomasInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2013
- The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics DataCancer Discovery, 2012
- Recent advances in the molecular understanding of glioblastomaJournal of Neuro-Oncology, 2012
- IDH mutations predict longer survival and response to temozolomide in secondary glioblastomaCancer Science, 2011
- Effector T-Cell Infiltration Positively Impacts Survival of Glioblastoma Patients and Is Impaired by Tumor-Derived TGF-βClinical Cancer Research, 2011
- Colorectal cancer prognosis depends on T-cell infiltration and molecular characteristics of the tumorLaboratory Investigation, 2011
- Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomasActa Neuropathologica, 2010
- The 2007 WHO Classification of Tumours of the Central Nervous SystemActa Neuropathologica, 2007
- Role of carbonic anhydrase IX expression in prediction of the efficacy and outcome of primary epirubicin/tamoxifen therapy for breast cancerEndocrine-Related Cancer, 2006